Slide 1: Corporate Presentation May 2026
DBV TECHNOLOGIES © 2026, DBV Technologies. All rights reserved Corporate Presentation I May 2026 EuronextDBV Paris: DBV | Corporate Technologies I Nasdaq: DBVT Overview
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward looking statements including, but not limited to, statements concerning DBV’s financial condition and forecast of its cash runway; the exercise by investors of warrants and pre-funded warrants issued in connection with the financing; the outco
Slide 3: Our Mission is to Develop Novel Treatments for Pediatric Food Allergy
Our Mission is to Develop Novel Treatments for Pediatric Food Allergy Global, late-stage, biopharmaceutical company Committed to transforming lives of children & families living with the daily burden of food allergy Pioneered VIASKIN® patch technology DBV’s novel approach to epicutaneous immunothera
Slide 4: Company Highlights (US)
Company Highlights (US) Two Distinct Opportunities Clear Regulatory Pathway Anticipated Clinical & Cash Position for TwoVIASKIN® Peanut Patch Distinct Opportunities for Both Programs Regulatory Milestones One BLA in 4-7 YO The successful VITESSE - BLA submission anticipated Cash and Cash Equivalents
Slide 5: Significant Market Opportunity for VIASKIN Peanut Patch
Significant Market Opportunity for VIASKIN® Peanut Patch ~670K Children Aged 1-7 Years Have Peanut Allergy in US1-3 1-3 years old 4-7 years old 280,000 Toddlers1-3 390,000 Children1-3 1. CDC National Population Projections 2014-2060 https://wonder.cdc.gov/population-projections-2014-2060.html 2. Gup
Slide 6: Anticipated Near-Term Milestones
Anticipated Near-Term Milestones Upcoming Milestones & Catalysts Anticipated in 2026 CHILDREN (4-7 years) BLA submission for 4-7 YO anticipated in 1H 20261 Eligible for Priority Review (~8 Months Total Vs ~12 months Total with Standard Review) TODDLERS (1-3 years) Completion of enrollment of COMFORT
Slide 7: EMA Provided Guidance for Marketing Authorization Application for Circular VIASKIN Peanut Patch
EMA Provided Guidance for Marketing Authorization Application (MAA) for the Circular VIASKIN® Peanut Patch in 1-7 Year Olds The unmet need for peanut allergy in Europe is significant: Estimated that 615,000 children ages 1 – 7 YO in the EU have peanut allergy1 Incidence of new diagnosis of ~81,0
Slide 8: The Science of Epicutaneous Immunotherapy (EPIT)
THE SCIENCE OF EPICUTANEOUS IMMUNOTHERAPY (EPIT) 8
Slide 9: EPIT Aims to Re-educate the Immune System Thus Suppressing the Allergic Response
Epicutaneous Immunotherapy (EPIT) Aims to Re-educate the Immune System Thus Suppressing the Allergic Response1-7 Regulatory T Cells act on the immune system to Antigen Presenting Cells suppress the allergic response EPIT delivers allergen capture allergen and induce to the skin unique Regulatory T C
Slide 10: VIASKIN Patch: Our Innovative Approach to Epicutaneous Immunotherapy
VIASKIN® Patch: Our Innovative Approach to Epicutaneous Immunotherapy1-3 A Novel Drug-Device Combination for Delivering Allergen Immunotherapy Adhesive Overlay PET Titanium Backing Condensation Chamber Allergen Adhesive Crown Condensation Chamber Allergen Solubilization formed by adhesive crown, all
Slide 11: VIASKIN Patch Uses Minimal Amounts of Allergen Designed to Induce Desensitization
VIASKIN® Patch Uses Minimal Amounts of Allergen Designed to Induce Desensitization1-3 1/1000th of a peanut is applied daily to the skin Allergen 3 years of treatment with VIASKIN® Peanut patch (250 µg) is equivalent in exposure VIASKIN® Patch amount to 1 peanut kernel Solubilized allergen is capture
Slide 12: Desensitization is Measured by Increases in Eliciting Dose
Desensitization is Measured by Increases Decrease in Reaction Risk with Increased in Eliciting Dose (ED) ED Following Allergen Immunotherapy ED = the amount of allergen that induces allergic symptoms1: SKIN: erythematous rash, scratching, hives, lip or face swelling UPPER RESPIRATORY: sneezing/itchi
Slide 13: U.S. Commercial Opportunity VIASKIN Peanut Patch
U.S. COMMERCIAL OPPORTUNITY VIASKIN® PEANUT PATCH NYSE American: PHGE
Slide 14: The Peanut Allergy Epidemic
The Peanut Allergy Epidemic OFTEN A LIFELONG BURDEN STARTING AT AN EARLY AGE 92% 41% of peanut allergy cases emerge by age of 71; have an accidental exposure within 3 years of ~80% will not outgrow their allergy2 diagnosis3 Reactions unpredictable and can be life-threatening Annual economic impact $
Slide 15: Current Treatment Options Are Often Not Ideal for Patients & Their Families
Current Treatment Options Are Often Not Ideal for Patients & Their Families1-4 Oral Immunotherapy (Approvedⱡ & Non-Proprietary) Omalizumab (anti-IgE Monoclonal Antibody)ⱡⱡ Complex dose escalation schedule, requiring multiple Fear of injection: visits to an allergist’s office that can each last >1 ho
Slide 16: VIASKIN Peanut Patch – A Potential Treatment Easily Incorporated into Busy Lives of Families
VIASKIN® Peanut Patch – A Potential Treatment for Peanut Allergy That Can Be Easily Incorporated into the Busy Lives of Families Potential Benefits of Epicutaneous Immunotherapy with VIASKIN® Peanut Patch Applied at home, once a day onto child’s back No treatment escalation requiring frequent doctor
Slide 17: Peanut Allergy Market Dynamics: Patients, Prescribers, Payers
PEANUT ALLERGY MARKET DYNAMICS The Patients The Prescribers The Payers 670K Children 4,500 Allergists 50 Payers ages 1 to 7 years old 1,2 in the US1,2 cover +85% of lives DBV plans to leverage its strong DBV expects a 50 to 70-person DBV expects an 8 to 10 account specialty sales force to cover 90%
Slide 18: Peanut Allergy Market Dynamics: Pediatricians and Parents
PEANUT ALLERGY MARKET DYNAMICS Pediatricians Parents 60K 7.2M Pediatricians Millennials in the US born between 1981 and 1996 Pediatricians (PEDs) overwhelmingly follow the Most millennials turn to digital spaces for health AAP guidance to refer families to an Allergist for information and advice imm
Slide 19: External Engagements: HCP Interactions Designed to Activate, Learn, and Inform
External Engagements: HCP Interactions Designed to Activate, Learn, and Inform HCP engagement, driven by the Medical Science Liaison (MSL team), is aimed at educating and gathering expert insights through 1:1 meetings, congress activities, and advisory boards 2026 Advisory Boards Insights gathering
Slide 20: VIASKIN Peanut is a Breakthrough Patch with Potential to Revolutionize Treatment
VIASKIN Peanut is a breakthrough patch with the potential to revolutionize treatment in a large market with significant unmet need, if approved DIFFERENTIATION: Ability to address peanut allergy with a non-invasive patch that creates sustainable differentiation SIZEABLE MARKET AT LAUNCH: Launch mome
Slide 21: VIASKIN Peanut Patch Program in Children Ages 4-7 Years Old
VIASKIN® Peanut Patch Program in Children Ages 4-7 Years Old DBV Technologies | Corporate Overview
Slide 22: VITESSE Study Design
VITESSE Study Design • 654 subjects ages 4-7 YO (vs target enrollment of 6001) • Largest immunotherapy clinical trial for this patient population2 • DBV’s CIRCULAR VIASKIN® Peanut patch (containing 250 μg peanut protein extract) Global Phase 3 Trial Randomized, double-blind, placebo-controlled VIASK
Slide 23: The VITESSE Phase 3 Study Met the Primary Endpoint
The VITESSE Phase 3 Study Met the Primary Endpoint † Treatment Responders P<0.001** Δ= 31.8% The treatment effect observed in (95% CI: 24.5, 39.0) VITESSE (31.8%) is consistent with the treatment effect observed in the Phase 3 EPITOPE (33.4%) study in 1-3-year-olds N=438 N=216 95% CI Lower Bound of
Slide 24: Significantly Greater Proportion of Treatment Responders Observed With VP250
Significantly Greater Proportion of Treatment Responders Observed With VP250, Regardless of Baseline ED Strata1 Treatment Responders2 at Month 12 by Baseline ED Strata (ITT population) 60 Baseline ED of ≤30 mg 60 Baseline ED of 100 mg p<0.0001 50 50 p<0.0001 49.3 Participants (%) 40 40 43.1 Δ=34.6%
Slide 25: Majority of VP250 Participants Increased Eliciting Dose by at Least Two Doses
The Majority of VP250 Participants Increased Their Eliciting Dose by at Least Two Doses1 Changes in Eliciting Dose at Month 122 100% 82.8% of VP250 participants 23.4% increased their ED, 80% suggesting response to treatment, Participants (%) 60.1% vs 47.9% on placebo 24.5% 60% ED increase (≥2 dose
Slide 26: VITESSE Safety Summary
VITESSE Safety Summary Safety results consistent with prior trials, which now encompass over 1,600 children and more than 1.1 million patch applications The most common Treatment Emergent Adverse Events (TEAEs) observed during VITESSE were mild local skin reactions at the patch application site Disc
Slide 27: VIASKIN Peanut Patch Program in Toddlers (Ages 1–3 Years Old)
VIASKIN® Peanut Patch Program in Toddlers (Ages 1–3-Years Old) DBV Technologies | Corporate Overview
Slide 28: Phase 3 EPITOPE: VIASKIN Peanut Patch in Toddlers 1-3 Years of Age
Phase 3 EPITOPE: VIASKIN® Peanut Patch in Toddlers 1-3 Years of Age Study Design for EPITOPE Pivotal Global Study1 & Open-Label Extension (OLE) to EPITOPE Study2 EPITOPE Open-Label Extension (“EPOPEX”) High % of subjects opted to stay on VP250 VP250 VP250 after Year 1 EPITOPE through 36 Months3,4 n=
Slide 29: Positive Month 12 Results from Phase 3 EPITOPE Study
Positive Month 12 Results from Phase 3 EPITOPE Study with Primary Endpoint Met & with a Favorable Safety & Tolerability Profile PRIMARY ENDPOINT MET 1-3 OTHER ENDPOINTS 1-3 SAFETY 1-3 67.0% of participants 64.2% of participants reached an ED VP250 was well-tolerated, on VP250 were of ≥1000 mg (equiv
Slide 30: EPITOPE OLE Shows Continued Improvement in Treatment Response Through 36 Months
EPITOPE Open-Label Extension Shows Continued Improvement in Treatment Response in Toddlers Through 36 MO1-4 • 175 subjects entered OLE study (out of 244 randomized to receive VP250 in EPITOPE1) • 166 subjects (95%) of those in the OLE underwent DBPCFC at Month 24 • 149 subjects (85%) underwent DBPCF
Slide 31: EPITOPE OLE Continued Improvement: ED ≥2000 mg and Completed Challenge
Data from EPITOPE Open-Label Extension Show Continued Improvement in Treatment Response in Toddlers Through 36 MO1-4 Eliciting Dose ≥2000 mg Completed Food Challenge* Without (Equivalent of 6-8 peanuts) Meeting Stopping Criteria *3444 mg cumulative dose consumed 100 100 Percentage of Participants Pe
Slide 32: Consistent Favorable Safety & Tolerability Profile in Toddlers
Study Results of VIASKIN® Peanut Patch Consistently Demonstrate a Favorable Safety & Tolerability Profile in Toddlers1-4 Frequency of Treatment-Related Local Skin Reactions Are Further Reduced After 3 Years of Treatment • Consistent with other studies5, local Year 1† Year 2 Year 3 application site r
Slide 33: Accelerated Approval Pathway for VIASKIN Peanut Patch in Toddlers
Accelerated Approval Pathway for VIASKIN® Peanut Patch in Toddlers FDA Accelerated Approval Pathway to Licensure Designed to Facilitate & Expedite Promising Therapies Current FDA Guidance for Accelerated Approval (AA) FDA Confirms an AA Pathway for Includes 3 Qualifying Criteria: VIASKIN® Peanut Pat
Slide 34: Summary: VIASKIN Peanut ─ Novel Drug-Device with Significant Market Potential
SUMMARY: VIASKIN Peanut ─ A Novel Drug-Device with Significant Market Potential High unmet need: medical consequence of accidental peanut consumption plus the ever-present impact on child and family’s quality of life Significant market size in BOTH indications Designed to meet outcome objectives of
Slide 35: Appendix: VIASKIN Pipeline, Manufacturing, Intellectual Property
Appendix 1 VIASKIN Pipeline Manufacturing Intellectual Property DBV Technologies | Corporate Overview
Slide 36: Our Long-Term Vision is to Realize the Full Potential of the VIASKIN Patch Technology
OUR LONG-TERM VISION IS TO REALIZE THE FULL POTENTIAL OF THE VIASKIN® PATCH TECHNOLOGY DEVELOPMENT STAGE PROGRAM & INDICATION PROGRAM & INDICATION Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Ages 4-7 years VIASKIN® peanut Food Allergy patch Ages 1-3 years (DBV712) Peanut Allergy Ages 6-12 months*
Slide 37: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio IP Protection in Various Countries, Encompassing: Core patch technology Condensation chamber Epicutaneous immunotherapy (EPIT) activates the immune system by allowing the Mechanism of action antigen to penetrate the upper layer of the epidermis (intact skin) Ma
Slide 38: Patch Manufacturing Capabilities
Patch Manufacturing Capabilities Integrated End-to-End Patch Manufacturing in Place Source Material Active Pharmaceutical Ingredient (API) Final Product Process Proprietary electrospray technology deposits a precise antigen dose without any adjuvant on a PET titanium backing film DBV Technologies |
Slide 39: Investor Relations Contacts
Investor Relations Jonathan Neely, VP & Head of IR +1 848-388-4584 jonathan.neely@dbv-technologies.com Public Relations and Media Brett Whelan +1 848-350-7622 brett.whelan@dbv-technologies.com Partnering and Licensing generalinquiries@dbv-technologies.com Clinical Trial Participation clinicaltrials@